US 9687522
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
granted A61KA61K38/02A61K38/07
Quick answer
US patent 9687522 (Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K38/02, A61K38/07, A61K38/16, A61P